PharmExec

Pfizer Receives Unsolicited Mini-Tender Offer for 1 Million Shares from Tutanota: Report

Tutanota offered $32 per Pfizer share for up to 1 million shares, expiring April 13, 2026, with plans to extend the bid until ...

Pfizer Reports Positive Results in Prostate Cancer Study

Pfizer reported positive topline results in its phase three study of talazoparib in combination with enzalutamide to treat metastatic hormone-sensitive prostate cancer. The study met its primary ...

Pfizer reports positive data from a Phase 2 study for the atopic dermatitis antibody

Pfizer said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive ...
Fierce Biotech

Pfizer Ignite, designed to accelerate promising biotech therapies, fizzles out

As pharmas like Eli Lilly and Roche bolster their biotech offerings, Pfizer is snuffing out its program designed to incubate new innovations from select companies, dubbed Pfizer Ignite. | As pharmas ...

Should You Avoid Pfizer? Here's the Key Risk to Watch

Pfizer has reached a turning point.
Seeking Alpha

Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance

Includes a one-time $1.35 billion Acquired In-Process R&D charge related to the in-licensing agreement with 3SBio, Inc. recorded in the third quarter of 2025 with an unfavorable impact of ...